Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis

Clovis Oncology Inc., maker of the ovarian and prostate cancer drug Rubraca, filed for bankruptcy over the weekend with a proposed deal in hand to sell its rights to a cancer therapy under development...

Menopause Supplement Industry To Grow To $22.7 Billion By 2028 As Women Seek Out Alternative Treatments

“The industry consists of companies selling unvalidated, poorly formulated, over-hyped products … [+]s which offer few, if any benefits.” This is why LYMA, a supplement specialist brand, has lau...